AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17302367 — intervention group
Group type: EXPERIMENTAL
Intervention: LB80380 120 mg once per day
Number of subjects: 29
Study 17302367 — intervention group
Group type: EXPERIMENTAL
Intervention: LB80380 240 mg once per day
Number of subjects: 29
Study 17302367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15455897 — intervention group
Group type: EXPERIMENTAL
Intervention: WebSET training tool for lumbar puncture
Number of subjects: 0
Study 15455897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 11097284 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% instilled 15 min prior to surgery
Number of subjects: 123
Study 11097284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brimonidine)
Number of subjects: 123
Study 8811473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of delmopinol hydrochloride applied 2 times a day for 7 days
Number of subjects: 14
Study 8811473 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous solution of delmopinol hydrochloride applied on previously placebo-treated surfaces
Number of subjects: 14
Study 8811473 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 14
Study 1569229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% delmopinol
Number of subjects: 64
Study 1569229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol
Number of subjects: 64
Study 1569229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol
Number of subjects: 64
Study 1569229 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 64
Study 1569229 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05%, 0.1%, and 0.2% delmopinol
Number of subjects: 64
Study 4043663 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (12.5 mM)
Number of subjects: 0
Study 4043663 — intervention group
Group type: COMPARATOR
Intervention: Choline chloride (control)
Number of subjects: 0
Study 4043663 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (and calcium)
Number of subjects: 0
Study 31336051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (5 stretching, 2 dynamic mobility, and 2 balance training exercises during warm-up)
Number of subjects: 237
Study 31336051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 237
Study 31336051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 237
Study 29454140 — intervention group
Group type: EXPERIMENTAL
Intervention: Group phone conferences (GP)
Number of subjects: 200
Study 29454140 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual phone calls (IP)
Number of subjects: 200
Study 29454140 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 200
Study 27235114 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy intervention group (MTG)
Number of subjects: 14
Study 27235114 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing group (SG)
Number of subjects: 14
Study 27235114 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group (CG)
Number of subjects: 14
Study 24877181 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 25-100 mg/m2 SC doses in patients with normal renal function (n=21)
Number of subjects: 27
Study 24877181 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 SC doses for 5 consecutive days in patients with severe renal impairment (n=6)
Number of subjects: 27
Study 24877181 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m2 SC doses (multiple doses)
Number of subjects: 27
Study 24877181 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine in patients with normal renal function (n=6)
Number of subjects: 27
Study 24877181 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine in patients with normal or impaired renal function
Number of subjects: 27
Study 22338070 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g whey protein
Number of subjects: 33
Study 22338070 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g whey protein
Number of subjects: 33
Study 22338070 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g whey protein
Number of subjects: 33
Study 19958428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three full‐face IPL treatments and six full‐face topical antioxidant applications (Group C)
Number of subjects: 30
Study 19958428 — intervention group
Group type: COMPARATOR
Intervention: Three full‐face IPL treatments (Group A)
Number of subjects: 30
Study 19958428 — intervention group
Group type: COMPARATOR
Intervention: Six weekly full‐face treatments of a pneumatically applied topical polyphenolic antioxidant solution (Group B)
Number of subjects: 30
Study 17554013 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater temporal distance since the transgression (Experiment 1)
Number of subjects: 0
Study 17554013 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective perception of temporal distance (Experiment 2)
Number of subjects: 0
Study 17554013 — intervention group
Group type: EXPERIMENTAL
Intervention: Real temporal distance perception (Experiment 3)
Number of subjects: 0
Study 15884262 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (50 mg oral doses)
Number of subjects: 34
Study 15884262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11606512 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9733031 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape of the genetic consultation
Number of subjects: 115
Study 9733031 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation
Number of subjects: 115
Study 8055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 1 mg
Number of subjects: 7
Study 8055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 2 mg
Number of subjects: 7
Study 8055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal butorphanol 4 mg
Number of subjects: 7
Study 8055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular butorphanol 1 mg
Number of subjects: 7
Study 8055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular butorphanol 2 mg
Number of subjects: 7
Study 8055737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular butorphanol 4 mg
Number of subjects: 7
Study 8055737 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 7
Study 8055737 — intervention group
Group type: COMPARATOR
Intervention: Transnasal placebo
Number of subjects: 7
Study 3056221 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunochemotherapy (streptococcus pyogenes preparation (picibanil) intramuscularly every week, plus either MFC or FME chemotherapy regimen)
Number of subjects: 138
Study 3056221 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (no further anticancer therapy)
Number of subjects: 138
Study 3056221 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative immunochemotherapy
Number of subjects: 138
Study 31742465 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (ePTFE) mesh
Number of subjects: 60
Study 31742465 — intervention group
Group type: COMPARATOR
Intervention: Other types of mesh (group B)
Number of subjects: 60
Study 29088393 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+MT+B
Number of subjects: 300
Study 29088393 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+B
Number of subjects: 300
Study 29088393 — intervention group
Group type: COMPARATOR
Intervention: EX
Number of subjects: 300
Study 29088393 — intervention group
Group type: COMPARATOR
Intervention: EX+MT
Number of subjects: 300
Study 28069060 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch, inelastic compression bandage
Number of subjects: 50
Study 28069060 — intervention group
Group type: COMPARATOR
Intervention: Standard wool and crepe bandage
Number of subjects: 50
Study 26213379 — intervention group
Group type: EXPERIMENTAL
Intervention: Coming Out Proud (COP) program
Number of subjects: 126
Study 26213379 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 126
Study 23774030 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BTX‐A)
Number of subjects: 16
Study 23774030 — intervention group
Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB (BTX‐B)
Number of subjects: 16
Study 21680253 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (to induce pain)
Number of subjects: 9
Study 17244767 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 600-mg dose of cyclosporine with a single 100-mg oral sitagliptin dose
Number of subjects: 8
Study 17244767 — intervention group
Group type: COMPARATOR
Intervention: Single oral 100-mg sitagliptin dose alone
Number of subjects: 8
Study 15258553 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin + pioglitazone 30 mg
Number of subjects: 40
Study 15258553 — intervention group
Group type: COMPARATOR
Intervention: metformin + placebo
Number of subjects: 40
Study 11832307 — intervention group
Group type: EXPERIMENTAL
Intervention: α-blockers
Number of subjects: 0
Study 11832307 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9427226 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic sensorimotor peripheral neuropathy (DSPN)
Number of subjects: 0
Study 9427226 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic autonomic neuropathy (DNA)
Number of subjects: 0
Study 7851369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal variable resistance test for 45 seconds
Number of subjects: 8
Study 7851369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal variable resistance test for 60 seconds
Number of subjects: 8
Study 7851369 — intervention group
Group type: EXPERIMENTAL
Intervention: Supramaximal variable resistance test for 90 seconds
Number of subjects: 8
Study 7851369 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-second test
Number of subjects: 8
Study 7851369 — intervention group
Group type: COMPARATOR
Intervention: Comparison of tests
Number of subjects: 8
Study 2701034 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic device therapy
Number of subjects: 58
Study 2701034 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 58
Study 786669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg methyl proscillaridin (oral administration)
Number of subjects: 16
Study 786669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg methyl proscillaridin (intravenous administration)
Number of subjects: 16
Study 786669 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg methyl proscillaridin (oral and iv administration)
Number of subjects: 16
Study 29722166 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1% ALN gel
Number of subjects: 90
Study 29722166 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus AV gel
Number of subjects: 90
Study 29722166 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo gel
Number of subjects: 90
Study 28746926 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine iontophoresis
Number of subjects: 18
Study 25920295 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics group (Lactobacillus casei, Shirota strain)
Number of subjects: 150
Study 25920295 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 25920295 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 23430102 — intervention group
Group type: EXPERIMENTAL
Intervention: Age + trunk flexor endurance
Number of subjects: 0
Study 23430102 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability + hip extensor strength
Number of subjects: 0
Study 21998479 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 1.5 g twice daily for 12 weeks
Number of subjects: 32
Study 21998479 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 400 mg twice daily for 12 weeks
Number of subjects: 32
Study 18444745 — intervention group
Group type: EXPERIMENTAL
Intervention: Making choices among consumer goods or college course options
Number of subjects: 0
Study 18444745 — intervention group
Group type: COMPARATOR
Intervention: Thinking about options without making choices
Number of subjects: 0
Study 18444745 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipating the choice task as enjoyable
Number of subjects: 0
Study 16927137 — intervention group
Group type: EXPERIMENTAL
Intervention: IV pantoprazole (40 mg once daily for 7 days)
Number of subjects: 78
Study 16927137 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pantoprazole (40 mg once daily for 7 days)
Number of subjects: 78
Study 16927137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 16927137 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/oral pantoprazole
Number of subjects: 78
Study 15742550 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg subcutaneously twice daily) plus optimized background regimen
Number of subjects: 995
Study 15742550 — intervention group
Group type: COMPARATOR
Intervention: Optimized antiretroviral regimen alone (control group)
Number of subjects: 995
Study 11269460 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 50
Study 11269460 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 50
Study 9849404 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN-alpha 2b) as adjuvant therapy
Number of subjects: 0
Study 9849404 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN-alpha 2b)
Number of subjects: 0
Study 9849404 — intervention group
Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 0
Study 10319136 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (0.5 mg oral digoxin)
Number of subjects: 12
Study 10319136 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (0.5 mg oral digoxin)
Number of subjects: 12
Study 10319136 — intervention group
Group type: COMPARATOR
Intervention: Formulation C (0.5 mg oral digoxin, standard)
Number of subjects: 12
Study 2687956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment with radiotherapy and chemotherapy
Number of subjects: 0
Study 2687956 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 2687956 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic radiation with chemotherapy
Number of subjects: 0
Study 2687956 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment after resection of rectal cancer
Number of subjects: 0
Study 2687956 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and concurrent 5-fluorouracil for squamous cancers of the anal canal
Number of subjects: 0
Study 53659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 1‐25 megaunits of penicillin
Number of subjects: 0
Study 53659 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound irrigation with 100mg of tetracycline in solution
Number of subjects: 0
Study 53659 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 0
Study 30714820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of immediate release (IR) and extended release (ER) methylphenidate taken at the same time
Number of subjects: 0
Study 30714820 — intervention group
Group type: COMPARATOR
Intervention: Single extended release (ER) methylphenidate dose
Number of subjects: 0
Study 29087804 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction treatment
Number of subjects: 44
Study 29087804 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-rotor stripping (ARS) treatment
Number of subjects: 44
Study 29087804 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-extraction treatment
Number of subjects: 44
Study 25373438 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dose low-molecular-weight heparin (LMWH) for 21 days
Number of subjects: 378
Study 25373438 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injections for 21 days
Number of subjects: 378
Study 23874588 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone capsules (80 mg/d total isoflavones, 51 mg/d aglucon units)
Number of subjects: 86
Study 23874588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 21334240 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (50 mg Xilonibsa 10% before examination)
Number of subjects: 109
Study 21334240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 109
Study 19209034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI)
Number of subjects: 147
Study 19209034 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 147
Study 17109339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A treatment for 2 weeks
Number of subjects: 0
Study 17109339 — intervention group
Group type: COMPARATOR
Intervention: Standardized antiretroviral therapy (ART)
Number of subjects: 0
Study 14716265 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm thick MTA
Number of subjects: 64
Study 14716265 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm thick MTA
Number of subjects: 64
Study 14716265 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm thick MTA
Number of subjects: 64
Study 14716265 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm thick MTA
Number of subjects: 64
Study 11239186 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (250 mg over 1 hour followed by 85 mg/h for 71 hours)
Number of subjects: 150
Study 11239186 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059 (500 mg over 1 hour followed by 170 mg/h for 71 hours)
Number of subjects: 150
Study 11239186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9227720 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol 24 micrograms twice daily
Number of subjects: 239
Study 9227720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 8119517 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive AV delay (156 to 63 ms)
Number of subjects: 8
Study 8119517 — intervention group
Group type: COMPARATOR
Intervention: Fixed AV delay (156 ms)
Number of subjects: 8
Study 3119693 — intervention group
Group type: EXPERIMENTAL
Intervention: Team‐oriented geriatric assessment by a multidisciplinary team
Number of subjects: 117
Study 3119693 — intervention group
Group type: COMPARATOR
Intervention: Traditional care by community internists
Number of subjects: 117
Study 29528961 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training (SUP)
Number of subjects: 36
Study 29528961 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised resistance training (UNSUP)
Number of subjects: 36
Study 29528961 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SUP and UNSUP
Number of subjects: 36
Study 30170586 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Exercise (blended physiotherapy intervention consisting of physiotherapy sessions and a web-application)
Number of subjects: 207
Study 30170586 — intervention group
Group type: COMPARATOR
Intervention: usual physiotherapy (control group)
Number of subjects: 207
Study 30170586 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Exercise
Number of subjects: 207
Study 27632893 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg BID
Number of subjects: 450
Study 27632893 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg BID
Number of subjects: 450
Study 27632893 — intervention group
Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg BID
Number of subjects: 450
Study 27632893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 24603321 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoes and standard care (deworming with albendazole and health education)
Number of subjects: 915
Study 24603321 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 915
Study 22411658 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL implantation with target postoperative refraction of +8.0 D for infants 28 to 48 days old and +6.0 D for those 49 days or older to younger than 7 months at surgery.
Number of subjects: 49
Study 22411658 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary IOL implantation with IOL power of 30.0 D or greater.
Number of subjects: 49
Study 22411658 — intervention group
Group type: EXPERIMENTAL
Intervention: Short axial length (<18 mm).
Number of subjects: 49
Study 18849079 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (or amitriptyline as a second choice) plus Interpersonal Psychotherapy modified for inpatients (IPT)
Number of subjects: 124
Study 18849079 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (or amitriptyline as a second choice) plus Clinical Management (CM)
Number of subjects: 124
Study 18849079 — intervention group
Group type: EXPERIMENTAL
Intervention: Early improvement within two weeks
Number of subjects: 124
Study 17202521 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16203762 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide + radiotherapy (n = 287)
Number of subjects: 573
Study 16203762 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (n = 286)
Number of subjects: 573
Study 12487221 — intervention group
Group type: EXPERIMENTAL
Intervention: DPI (Dry Powder Inhaler) - 200 microg of inhaled budesonide twice daily for 1 month
Number of subjects: 15
Study 12487221 — intervention group
Group type: COMPARATOR
Intervention: pMDI + spacer (Pressurized Metered-Dose Inhaler with spacer) - 200 microg of inhaled budesonide twice daily for 1 month
Number of subjects: 15
Study 9657569 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm ozone
Number of subjects: 12
Study 9657569 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 12
Study 8579313 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 71
Study 8579313 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 71